New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
16:56 EDTZGNXZogenix competitor gets FDA approval for abuse-deterrent ER oxycodone
The FDA approved Targiniq ER, an extended-release/long-acting opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the productís abuse-deterrent properties consistent with the FDAís 2013 draft guidance for industry, the FDA stated. The FDA is requiring postmarketing studies of Targiniq ER, to assess the serious risks of misuse, abuse, increased sensitivity to pain, addiction, overdose, and death associated with long term use beyond 12 weeks. The FDA is also requiring postmarketing studies to further assess the effects of the abuse-deterrent features on the risk for abuse of Targiniq ER. In addition, Targiniq ER is part of the ER/LA Opioid Analgesics Risk Evaluation and Mitigation Strategy. Targiniq ER is manufactured by Purdue Pharma. Zogenix has a competing pain killer drug called Zohydro ER.
News For ZGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
07:21 EDTZGNXZogenix 4.75M share Secondary priced at $18.00
The deal size was increased to 4.75M shares from 3.8M shares. Leerink and Stifel acted as joint book running managers for the offering.
July 28, 2015
19:10 EDTZGNXOn The Fly: After Hours Movers
Subscribe for More Information
16:40 EDTZGNXZogenix files to sell 3.8M shares of common stock
Subscribe for More Information
July 23, 2015
17:15 EDTZGNXIntegrated Core Strategies reports 5.6% passive stake in Zogenix

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use